Atara Biotherapeutics (ATRA) Research & Development (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Research & Development for 14 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 81.6% year-over-year to $1.3 million; the trailing twelve-month figure through Jun 2026 stood at $4.2 million (down 96.08% YoY), and the FY2025 full-year result was $37.4 million, down 75.28% from the prior year.
• Research & Development grew to $1.3 million in Q2 2026 per ATRA's latest filing, from $164000.0 in the prior quarter.
• Across five years, Research & Development topped out at $75.0 million in Q1 2022 and bottomed at -$223000.0 in Q4 2025.
• Historically, Research & Development has averaged $38.2 million across 5 years, with a median of $44.7 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Research & Development increased 17.02% in 2022, then plunged 100.78% in 2025.
• Over 5 years, Research & Development stood at $62.5 million in 2022, then fell by 20.66% to $49.6 million in 2023, then sank by 42.09% to $28.7 million in 2024, then slumped by 100.78% to -$223000.0 in 2025, then jumped by 703.14% to $1.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $1.3 million, $164000.0, and -$223000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.